Rank 56 • AI & Clinical Intelligence
ArteraAI
Develops AI-driven prognostic and predictive tests to personalize cancer treatment plans, starting with prostate cancer.
Visit website- Signal Score
- 87.2
- Total raised
- $110M
- Stage
- Series A
- Founded
- 2021
- Headquarters
- San Francisco, USA
- Region
- North America
Their signal
ArteraAI is validated by phase III clinical trials, and its AI-enabled pathology tests are increasingly covered by national payers.
Signal Score 87.2editorial estimate, see how it is built
Total raised, quality of investors and recency of the last round.
Revenue trajectory, customer count, hiring and market pull.
Peer-reviewed evidence, FDA/CE clearances and live health-system deployments.
Founder track record, clinical depth on the bench and technical leadership.
Search presence, press coverage, founder and brand reach, and how often the company shows up where buyers look.
Also in AI & Clinical Intelligence
Figures are subjective research desk estimates compiled from public sources and refreshed daily, published as editorial commentary. Company marks are shown for identification only and imply no endorsement or affiliation. Want a correction, an update or removal? and see our corrections and removals policy.